Back to top

LACOG 0218 – Hercules

  /    /  LACOG 0218 – Hercules

A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer

Type of Study: Clinical Trial

Sponsor / Support: LACOG

Primary Objectives: The primary objective is to evaluate if pembrolizumab improves Overall Response Rate in first-line setting associated with platinum-based chemotherapy.

Design: This is a phase II, multicenter, open-label, one-arm interventional trial. 

Sample Size: 33 patients

Principal Investigator: Fernando Cotait Maluf

Countries LATAM: Brazil

Study Website: https://www.estudohercules.com.br/

Clinicaltrials.gov Identifier: NCT04224740

The study is open to patients participation in the following research sites:

Oncocentro Ceará / Fortaleza / CE / Brazil

BP - A Beneficência Portuguesa de São Paulo / São Paulo / SP

Clínica Oncológica Brasil / Belém / PA / Brazil

Hospital Erasto Gaertner / Curitiba / PR / Brazil

Hospital do Câncer de Barretos / Barretos / SP / Brazil

Hospital Amaral Carvalho / Jaú / SP / Brazil

Instituto do Câncer do Ceará / Fortaleza / CE / Brazil

INCA - Instituto Nacional de Câncer / Rio de Janeiro / RJ / Brazil

Hospital Universitário de Brasília / Brasília / DF / Brazil

ICESP - Instituto do Câncer do Estado de São Paulo / São Paulo / SP / Brazil